78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 33; pp. S1462 - S1463
Main Authors: Oh, D-Y., He, A.R., Qin, S., Chen, L-T., Okusaka, T., Vogel, A., Kim, J.W., Lee, T., Lee, M.A., Kitano, M., Burris, H.A., Bouattour, M., Tanasanvimon, S., Zaucha, R.E., Avallone, A., Cundom, J.E., Rokutanda, N., Żotkiewicz, M., Cohen, G., Valle, J.W.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-11-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2022.10.114